<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The majority of patients with <z:e sem="disease" ids="C0221013" disease_type="Disease or Syndrome" abbrv="">systemic mast cell disease</z:e> express the <z:chebi fb="0" ids="45783">imatinib</z:chebi>-resistant Asp816Val (D816V) mutation in the KIT receptor tyrosine kinase </plain></SENT>
<SENT sid="1" pm="."><plain>Limited treatment options exist for aggressive systemic <z:hpo ids='HP_0100495'>mastocytosis</z:hpo> (ASM) and mast cell <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>We evaluated whether PKC412, a small-molecule inhibitor of KIT with a different chemical structure from <z:chebi fb="0" ids="45783">imatinib</z:chebi>, may have therapeutic use in advanced SM with the D816V KIT mutation </plain></SENT>
<SENT sid="3" pm="."><plain>We treated a patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> (with an associated <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>)/<z:hpo ids='HP_0005547'>myeloproliferative disorder</z:hpo> [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e>]) based on in vitro studies demonstrating that PKC412 could inhibit D816V KIT-transformed Ba/F3 cell growth with a 50% inhibitory concentration (IC50) of 30 nM to 40 nM </plain></SENT>
<SENT sid="4" pm="."><plain>The patient exhibited a partial response with significant resolution of liver function abnormalities </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, PKC412 treatment resulted in a significant decline in the percentage of peripheral blood mast cells and serum <z:chebi fb="11" ids="18295">histamine</z:chebi> level and was associated with a decrease in KIT phosphorylation and D816V KIT mutation frequency </plain></SENT>
<SENT sid="6" pm="."><plain>The patient died after 3 months of therapy due to progression of her <z:e sem="disease" ids="C1301355" disease_type="Neoplastic Process" abbrv="">MDS/MPD</z:e> to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="7" pm="."><plain>This case indicates that KIT tyrosine kinase inhibition is a feasible approach in SM, but single-agent clinical efficacy may be limited by <z:e sem="disease" ids="C1516669" disease_type="Neoplastic Process" abbrv="">clonal evolution</z:e> in the advanced leukemic phase of this disease </plain></SENT>
</text></document>